Cargando…

Effects of Risperidone and Paliperidone on Brain-Derived Neurotrophic Factor and N400 in First-Episode Schizophrenia

BACKGROUND: Risperidone and paliperidone have been the mainstay treatment for schizophrenia and their potential role in neuroprotection could be associated with brain-derived neurotrophic factor (BDNF) and N400 (an event-related brain potential component). So far, different effects on both BDNF and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Rong-Qin, Lin, Chong-Guang, Zhang, Wei, Lin, Xiao-Dong, Chen, Xing-Shi, Chen, Ce, Zhang, Li-Jun, Huang, Zi-Ye, Chen, Guang-Dong, Xu, Da-Li, Lin, Zhi-Guang, Zhang, Ming-Dao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166445/ https://www.ncbi.nlm.nih.gov/pubmed/30246715 http://dx.doi.org/10.4103/0366-6999.241802

Ejemplares similares

Follow-up of N400 in the Rehabilitation of First-episode Schizophrenia
por: Du, Xiang-Dong, et al.
Publicado: (2015)

Effects of Repetitive Transcranial Magnetic Stimulation Treatment on Event-Related Potentials in Schizophrenia
por: Lin, Xiao-Dong, et al.
Publicado: (2018)

Comparative Pharmacology of Risperidone and Paliperidone
por: Corena-McLeod, Maria
Publicado: (2015)

Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
por: Alphs, Larry, et al.
Publicado: (2013)

Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis
por: Turkoz, Ibrahim, et al.
Publicado: (2011)

S56. SWITCHING FROM RISPERIDONE TO PALIPERIDONE PALMITATE IN SCHIZOPHRENIA: CHANGES IN COGNITIVE FUNCTION
por: Tost Bonet, Meritxell, et al.
Publicado: (2020)

Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate
por: Patel, Charmi, et al.
Publicado: (2019)

The effects of concurrent oral paliperidone or risperidone use with paliperidone long-acting injection
por: Stump, Trevor A., et al.
Publicado: (2021)

Audit on prolactin monitoring for patients on oral risperidone, intramuscular risperidone, and intramuscular paliperidone
por: Bader, Mohamed
Publicado: (2021)

Determination of Plasma Concentration Reference Ranges for Risperidone and Paliperidone
por: Korell, J, et al.
Publicado: (2017)

PM409. Paliperidone Palmitate 3-Monthly vs. 1-Monthly Injectable in Schizophrenia Patients with or without Prior Exposure to Oral Risperidone or Paliperidone
por: Mathews, Maju, et al.
Publicado: (2016)

Paliperidone Palmitate versus Risperidone Long-Acting Injectable in Patients with Schizophrenia: A Meta-Analysis of Efficacy and Safety
por: Zhao, Mingjun, et al.
Publicado: (2023)

Evidence based administration of risperidone and paliperidone for the treating conduct disorder
por: Ghanizadeh, Ahmad
Publicado: (2013)

Healthcare Resource Utilization and Costs Among Patients With Schizophrenia Switching From Oral Risperidone/Paliperidone to Once-Monthly Paliperidone Palmitate: A Veterans Health Administration Claims Analysis
por: Patel, Charmi, et al.
Publicado: (2020)

Association of telomere length and mitochondrial DNA copy number with risperidone treatment response in first-episode antipsychotic-naïve schizophrenia
por: Li, Zongchang, et al.
Publicado: (2015)

Obesity, antioxidants and negative symptom improvement in first-episode schizophrenia patients treated with risperidone
por: Gao, Zhiyong, et al.
Publicado: (2023)

Relationship between TNF-α levels and psychiatric symptoms in first-episode drug-naïve patients with schizophrenia before and after risperidone treatment and in chronic patients
por: Lin, Chen, et al.
Publicado: (2021)

RISPERIDONE IN SCHIZOPHRENIA
por: Agashe, Mohan, et al.
Publicado: (1999)

RISPERIDONE IN SCHIZOPHRENIA
por: Kumar, P.N. Suresh
Publicado: (1999)

Evaluation of paliperidone on social function in patients with chronic schizophrenia
por: Gu, Yan, et al.
Publicado: (2018)

Fat-mass and obesity-associated gene polymorphisms and weight gain after risperidone treatment in first episode schizophrenia
por: Song, Xueqin, et al.
Publicado: (2014)

Dosing strategies for switching from oral risperidone to paliperidone palmitate: Effects on clinical outcomes
por: Hsia, Stephanie L., et al.
Publicado: (2018)

Drug utilization of paliperidone in adolescent schizophrenia patients: A retrospective cohort study in China
por: Dong, S., et al.
Publicado: (2021)

Risk factors for medication-induced amenorrhea in first-episode female Chinese patients with schizophrenia treated with risperidone
por: Chen, Haizhi, et al.
Publicado: (2013)

Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics
por: Schreiner, A, et al.
Publicado: (2015)

Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial
por: Takekita, Yoshiteru, et al.
Publicado: (2016)

The Effects of Combined Social Cognition and Interaction Training and Paliperidone on Early-Onset Schizophrenia
por: Li, Yichen, et al.
Publicado: (2020)

Striatum-related spontaneous coactivation patterns predict treatment response on positive symptoms of drug-naive first-episode schizophrenia with risperidone monotherapy
por: Zong, Xiaofen, et al.
Publicado: (2023)

Tachycardia during Treatment with Risperidone and Paliperidone Palmitate in a Patient without Previous Cardiovascular Disease
por: Orlins, Zachary, et al.
Publicado: (2021)

Methylome-wide association study of different responses to risperidone in schizophrenia
por: Du, Huihui, et al.
Publicado: (2022)

Benefits and harms of Risperidone and Paliperidone for treatment of patients with schizophrenia or bipolar disorder: a meta-analysis involving individual participant data and clinical study reports
por: Hodkinson, Alexander, et al.
Publicado: (2021)

RISPERIDONE IN INDIAN PATIENTS WITH SCHIZOPHRENIA
por: Duggal, Harpreet S., et al.
Publicado: (1999)

RISPERIDONE IN INDIAN PATIENTS WITH SCHIZOPHRENIA
por: Agarwal, A.K., et al.
Publicado: (1998)

Correlation of hair risperidone concentration and serum level among patients with schizophrenia
por: Sun, Xiujia, et al.
Publicado: (2019)

Pharmacokinetic-Pharmacodynamic Modeling of the D(2) and 5-HT(2A) Receptor Occupancy of Risperidone and Paliperidone in Rats
por: Kozielska, Magdalena, et al.
Publicado: (2012)

A comparison of the metabolic side-effects of the second-generation antipsychotic drugs risperidone and paliperidone in animal models
por: Boyda, Heidi N., et al.
Publicado: (2021)

Comparative study of clozapine versus risperidone in treatment-naive, first-episode schizophrenia: A pilot study
por: Sahni, Sukhtej, et al.
Publicado: (2016)

Paliperidone: the evidence of its therapeutic value in schizophrenia
por: Kantrowitz, Joshua, et al.
Publicado: (2007)

Once-monthly paliperidone injection for the treatment of schizophrenia
por: Bishara, Delia
Publicado: (2010)

PM394. The outcome of paliperidone palmitate in schizophrenia
por: Ju, Po-Chung
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_a6u405923si2p2liafth2721o8